Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 612 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

The Reproducibility and Clinical Utility of an Abbreviated Fat Tolerance Test

NCT04437459
Conditions
Dyslipidemias, Metabolic Syndrome
Interventions
High-fat shake, Pure glucose solution
Other
Lead sponsor
Oklahoma State University
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stillwater, Oklahoma
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Conditions
Diabetes Mellitus, Type 2
Interventions
semaglutide, oral glucose-lowering medications (commercially available)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more
Conditions
Insulin Resistance, Diabetes Mellitus, Abnormal Glucose Metabolism
Interventions
Liothyronine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults

NCT01419535
Conditions
Endocrine Disease, Diabetes
Interventions
Mifepristone, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
35 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prediabetes, Type 2 Diabetes (T2DM)
Interventions
Vitamin D (Cholecalciferol ), Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years to 74 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Head and Neck Cancer
Interventions
ZD 1839 500mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rocky Mountain Diabetes and Osteoporosis Center
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Idaho Falls, Idaho
Not listed No phase listed Observational Accepts healthy volunteers

Fasting Predictors of OGTT and MMTT Response

NCT01998867
Conditions
Prediabetes, Hypertension, Obesity, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Health Diagnostic Laboratory, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Enrolling by invitation Not applicable Interventional

Glycemic Impact of NNS Via the Gut Microbiome

NCT07868432
Conditions
Prediabetes
Interventions
Sucralose
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
35 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332
Conditions
Type 1 Diabetes
Interventions
Alprazolam, control group
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Conditions
Pre-diabetes
Interventions
L-Arabinose and Chromium, Sucrose without dietary Supplement
Dietary Supplement
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Conditions
Sedentary Behavior, Insulin Sensitivity, Sedentary Lifestyle
Interventions
SIT, ACTIVE, EX
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SGLT-2 inhibitor, SGLT2 inhibitor
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Not applicable Interventional Accepts healthy volunteers

Fructose-induced Hepatic De Novo Lipogenesis in Adolescents With Obesity

NCT03567837
Conditions
Adolescent Obesity
Interventions
Fructose + Glucose Beverage
Other
Lead sponsor
The Rogosin Institute
Other
Eligibility
12 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Congenital Disorders of Glycosylation
Interventions
D-Galactose
Dietary Supplement
Lead sponsor
Tulane University
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Altering Physical Activity on Cardiometabolic Health

NCT01879059
Conditions
Insulin Resistance
Interventions
Exercise
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
19 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Columbia, Missouri
Recruiting Phase 2 Interventional Accepts healthy volunteers

Splanchnic Venous Capacitance in Postural Tachycardia Syndrome

NCT05375968
Conditions
Postural Tachycardia Syndrome (POTS)
Interventions
Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients, Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls, Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2, Compare change is SVC and SMA flow due to saline
Diagnostic Test · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee